VCIM
IMVT icon

Velan Capital Investment Management’s Immunovant IMVT Stock Holding History

Velan Capital Investment Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-27,500
Closed -$1.16M – 24
2023
Q4 		$1.16M Buy
+27,500
New +$1.01M 0.68% 17

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Velan Capital Investment Management's IMVT Position: Q1 2024 in Review

Velan Capital Investment Management sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 27,500 shares — an estimated $1.16M sold.

Velan Capital Investment Management first reported a position in IMVT in Q4 2023 and held it in 1 quarter. The position peaked at $1.16M in Q4 2023. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Velan Capital Investment Management reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • Velan Capital Investment Management sold 27,500 Immunovant shares in Q1 2024, an estimated $1.16M.
  • Velan Capital Investment Management first reported a position in Immunovant in Q4 2023 and held it in 1 quarter.
  • Velan Capital Investment Management's Immunovant position peaked at $1.16M in Q4 2023.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Velan Capital Investment Management's 13F filing for Q1 2024, filed 14 May 2024.